Synexus has acquired three more clinical trial centres in Poland.
Dr. Andrzej Opadczuk will continue to manage the centres and will report to Dr. Christian Tueni, vice president, Synexus CEE. The management of the new centres will be trained in the Synexus Quality Assurance System and will follow the worldwide SOPs, which ensure efficient clinical practice and patient care in all Synexus Dedicated Research Centres. The centres will change their name to Synexus immediately, said the company.
Michael Fort, chief executive of Synexus, said: “This acquisition provides us with access to millions more patients and a wider range of therapy areas. The Synexus model continues to gain ground with our clients in pharma who recognise the benefits that the streamlined recruitment processes the Dedicated Research Centres deliver, namely helping to speed up trials, reduce costs and drive up quality. We are actively looking for further acquisitions, and in particular to increase our presence in India. These new centres will ensure that our growth in 2008 will be repeated in 2009.”